Published in Neurobiol Aging on August 31, 2008
Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci (2011) 2.60
Multi-dimensional mass spectrometry-based shotgun lipidomics and novel strategies for lipidomic analyses. Mass Spectrom Rev (2011) 2.39
Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging (2009) 2.14
Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim Biophys Acta (2010) 1.24
Novel advances in shotgun lipidomics for biology and medicine. Prog Lipid Res (2015) 0.95
The pro-neurotrophin receptor sortilin is a major neuronal apolipoprotein E receptor for catabolism of amyloid-β peptide in the brain. J Neurosci (2013) 0.90
Specific changes of sulfatide levels in individuals with pre-clinical Alzheimer's disease: an early event in disease pathogenesis. J Neurochem (2013) 0.85
Cholesterol increases ventricular volume in a rabbit model of Alzheimer's disease. J Alzheimers Dis (2012) 0.83
Dietary cholesterol impairs memory and memory increases brain cholesterol and sulfatide levels. Behav Neurosci (2010) 0.83
Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease? Clin Lipidol (2012) 0.81
Sulfatides facilitate apolipoprotein E-mediated amyloid-beta peptide clearance through an endocytotic pathway. J Neurochem (2008) 0.81
The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease. Mol Neurobiol (2010) 0.80
Chronic caloric restriction attenuates a loss of sulfatide content in PGC-1α-/- mouse cortex: a potential lipidomic role of PGC-1α in neurodegeneration. J Lipid Res (2011) 0.80
The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease. Biomed Res Int (2014) 0.79
Neurometabolic roles of ApoE and Ldl-R in mouse brain. J Bioenerg Biomembr (2015) 0.79
Ceramide and Related-Sphingolipid Levels Are Not Altered in Disease-Associated Brain Regions of APP and APP/PS1 Mouse Models of Alzheimer's Disease: Relationship with the Lack of Neurodegeneration? Int J Alzheimers Dis (2010) 0.76
APP Function and Lipids: A Bidirectional Link. Front Mol Neurosci (2017) 0.75
Novel molecular insights into the critical role of sulfatide in myelin maintenance/function. J Neurochem (2016) 0.75
A rapid method of total lipid extraction and purification. Can J Biochem Physiol (1959) 173.74
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev (2005) 5.98
APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol (1997) 4.29
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.07
Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci (1997) 2.91
Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell (1996) 2.53
Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem (2002) 2.45
Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol (2000) 2.21
Toward fingerprinting cellular lipidomes directly from biological samples by two-dimensional electrospray ionization mass spectrometry. Anal Biochem (2004) 2.17
Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest (2000) 2.11
Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol (2003) 1.78
The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease. J Cell Mol Med (2005) 1.62
Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci (2003) 1.58
Alterations in lipid homeostasis of mouse dorsal root ganglia induced by apolipoprotein E deficiency: a shotgun lipidomics study. J Neurochem (2007) 1.51
Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia (2006) 1.49
Apolipoprotein E, amyloid, and Alzheimer disease. Mol Interv (2002) 1.42
Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc Natl Acad Sci U S A (1996) 1.41
Alkaline methanolysis of lipid extracts extends shotgun lipidomics analyses to the low-abundance regime of cellular sphingolipids. Anal Biochem (2007) 1.22
Shotgun lipidomics identifies a paired rule for the presence of isomeric ether phospholipid molecular species. PLoS One (2007) 1.19
Metabolic and functional aspects of sulfogalactolipids. Biochim Biophys Acta (1994) 1.19
Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. J Biol Chem (2002) 1.18
Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics. J Neurochem (2007) 1.18
Abundance of triacylglycerols in ganglia and their depletion in diabetic mice: implications for the role of altered triacylglycerols in diabetic neuropathy. J Neurochem (2006) 1.10
Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study. Cell Mol Biol (Noisy-le-grand) (2003) 1.07
LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res Mol Brain Res (2002) 1.03
Galactosphingolipids and axono-glial interaction in myelin of the central nervous system. Cell Tissue Res (1998) 1.02
Endosomes and lysosomes play distinct roles in sulfatide-induced neuroblastoma apoptosis: potential mechanisms contributing to abnormal sulfatide metabolism in related neuronal diseases. Biochem J (2008) 0.98
Demyelination and altered expression of myelin-associated glycoprotein isoforms in the central nervous system of galactolipid-deficient mice. J Neurosci Res (1998) 0.96
LDL receptor-related protein (LRP) in Alzheimer's disease: towards a unified theory of pathogenesis. Microsc Res Tech (2000) 0.93
Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol Med (2000) 0.91
Accumulation of sulfatide in neuronal and glial cells of arylsulfatase A deficient mice. J Neurocytol (2004) 0.88
Regional variation in the distribution of apolipoprotein E and A beta in Alzheimer's disease. J Neuropathol Exp Neurol (1995) 0.85
Expression of the myelin and oligodendrocyte progenitor marker sulfatide in neurons and astrocytes of adult rat brain. J Neurosci Res (2002) 0.82
Sulfatides facilitate apolipoprotein E-mediated amyloid-beta peptide clearance through an endocytotic pathway. J Neurochem (2008) 0.81
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A (2003) 6.46
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci (2003) 5.00
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 4.92
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest (2002) 4.22
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron (2004) 4.21
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron (2008) 3.98
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res (2006) 3.64
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci (2002) 3.50
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 3.22
Sleep quality and preclinical Alzheimer disease. JAMA Neurol (2013) 3.11
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci (2009) 2.76
A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A (2003) 2.68
Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med (2012) 2.66
Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry (2002) 2.59
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 2.58
Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science (2008) 2.53
Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res (2004) 2.50
Automated lipid identification and quantification by multidimensional mass spectrometry-based shotgun lipidomics. Anal Chem (2009) 2.44
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem (2012) 2.42
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A (2011) 2.39
CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res (2007) 2.31
Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci (2012) 2.26
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol (2010) 2.25
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci (2009) 2.20
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology (2013) 2.19
ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem (2004) 2.19
Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci (2005) 2.17
Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem (2003) 2.15
Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem (2002) 2.13
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron (2013) 2.13
Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry (2006) 2.05
Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron (2009) 2.03
Modulating sphingolipid biosynthetic pathway rescues photoreceptor degeneration. Science (2003) 2.02
CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J Biol Chem (2007) 2.02
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest (2008) 2.01
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem (2006) 1.98
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem (2005) 1.91
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.90
Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A (2007) 1.89
Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest (2007) 1.88
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain (2012) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain (2010) 1.80
CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance. J Lipid Res (2010) 1.79
Electromagnetic controlled cortical impact device for precise, graded experimental traumatic brain injury. J Neurotrauma (2007) 1.79
Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol (2003) 1.78
Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis (2002) 1.74
Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One (2011) 1.74
A regulatory role for 1-acylglycerol-3-phosphate-O-acyltransferase 2 in adipocyte differentiation. J Biol Chem (2006) 1.73
Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol (2007) 1.70
IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci (2005) 1.69
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol (2009) 1.68
Lysosomal sorting of amyloid-β by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. Sci Transl Med (2014) 1.67
Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol Dis (2006) 1.67
Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci (2006) 1.65
Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol (2004) 1.64
The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem (2005) 1.63
Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol (2006) 1.60
Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. JAMA Neurol (2013) 1.60
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry (2010) 1.59
SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet (2010) 1.58
Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci (2003) 1.58
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58